This inventor holds 8 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Shionogi Company Limited, Hokkaido University. Active years: 2013-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Osaka, JP (2014)
- Toyonaka, JP (2013 - 2023)
Company Filing History:


Years Active: 2013-2023
Title: Junji Onoda: Innovator in Monoclonal Antibody Research
Introduction
Junji Onoda is a prominent inventor based in Toyonaka, Japan. He has made significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies. With a total of 8 patents to his name, Onoda's work has the potential to impact the treatment of various medical conditions.
Latest Patents
One of Onoda's latest patents is a monoclonal antibody against Nav1.7. The objective of this invention is to provide a novel monoclonal antibody that targets Nav1.7, which is crucial for pain and pruritus management. This invention discloses a monoclonal antibody or its antibody fragment, characterized by specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain). The application of this monoclonal antibody can be significant in treating or preventing pain and related conditions. Another notable patent involves a method of inhibiting the enzymatic activity of vascular endothelial lipase using a monoclonal antibody. This invention provides a monoclonal antibody or a fragment that selectively inhibits the enzymatic activity of vascular endothelial lipase, offering potential therapeutic benefits for arteriosclerosis and metabolic syndrome.
Career Highlights
Throughout his career, Junji Onoda has worked with esteemed organizations such as Shionogi Company Limited and Hokkaido University. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Onoda has collaborated with notable colleagues, including Tatsuya Takahashi and Shoichi Naito. These partnerships have further enriched his research endeavors and have led to advancements in monoclonal antibody technology.
Conclusion
Junji Onoda's innovative work in monoclonal antibody research exemplifies the impact of dedicated inventors in the medical field. His contributions hold promise for improving treatment options for various health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile